OGT SureSeq NGS panels with QIAGEN QCI Interpret tertiary analysis software

A new partnership between OGT and QIAGEN Digital Insights (QDI) expands OGT’s bioinformatics capabilities by integrating QIAGEN’s advanced tertiary analysis solution, QCI Interpret, with the former’s SureSeq NGS panels. Purpose-built for variant interpretation and clinical reporting, QCI Interpret delivers AI-powered, expert-curated classifications along with oncologist-reviewed summaries and transparent evidence links. Through this collaboration, SureSeq NGS panel users gain access to streamlined, high-confidence genomic insights and efficient, scalable reporting from sample to result.

QDI has built an expert-curated knowledge base of genomic and bioinformatic content, serving as the foundation of QCI Interpret. By combining the clinical precision of expert (MD/PhD) curation with the speed and scalability of AI-powered automation, QCI Interpret enables labs to deliver high-confidence variant interpretation and reporting. It empowers SureSeq users with transparent variant classifications, oncologist-reviewed summaries and on-demand interpretations — streamlining the path from sequencing to final report.

OGT’s SureSeq NGS products have been developed with hybridisation-based detection capabilities that enable clinical research labs to effortlessly achieve comprehensive genomic profiling of their samples and minimise the risk of missing variants. Combined with the consistency of QIAGEN’s software, labs gain access to an end-to-end workflow for fast, well-informed and confident insights, increasing users’ confidence in variant classification. Supporting SureSeq workflows with transparent variant classifications, oncologist-reviewed insights and flexible reporting helps users to scale confidently, reduce turnaround times, and improve outcomes for patients.